|Mr. Andrew McLean||CEO & Exec. Director||885.18k||N/A||N/A|
|Mr. Darren Smith M.B.A., B.Bus., FCPA||CFO & Company Sec.||559.13k||N/A||1965|
|Mr. Nigel Lange||Chief Commercial Officer||749.75k||N/A||N/A|
|Dr. Thomas Duthy Ph.D.||Global Investor Relations Mang.||N/A||N/A||N/A|
|Nathalie Amoury Pharmd||Director of Global Marketing & Communications||N/A||N/A||N/A|
Sirtex Medical Limited, a life-sciences company, develops and delivers oncology treatments using novel small particle technology in the Asia Pacific, Europe, the Middle East and Africa, and North and South America. Its lead product includes SIR-Spheres Y-90 resin microspheres, a targeted radiation therapy for the treatment of liver tumours. The company is headquartered in North Sydney, Australia.
Sirtex Medical Limited’s ISS Governance QualityScore as of April 1, 2018 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 1; Compensation: 10.